34
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emerging evidence suggests the composition of the tumour microenvironment (TME) correlates with clinical outcome and that each tumour type has a unique TME including a variable population of inflammatory cells. We performed immunohistochemistry on 65 phaeochromocytoma and paraganglioma (PPGL) tumour samples with 20 normal adrenal medulla samples for comparison. The immune cells assessed were macrophages, lymphocytes and neutrophils, and we compared the proportion of infiltration of these immune cells with clinical and histopathological factors. There was a higher proportion of immune cells in tumour tissue compared to non-neoplastic adrenal medulla tissue, with a predominance of macrophages. There was a higher proportion of M2:M1 macrophages and T-helper lymphocytes in aggressive tumours compared to indolent ones. For SDHB-associated tumours, there was a higher proportion of M2 macrophage infiltration, with higher M2:M1 in aggressive SDHB PPGLs compared to indolent tumours. These data demonstrate that immune cells do infiltrate the TME of PPGLs, confirming that PPGLs are immunologically active tumours. Differences in the TME of PPGLs were observed between aggressive and indolent tumours. These differences could potentially be exploited as an aid in predicting tumour behaviour.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: found

          Hallmarks of Cancer: The Next Generation

          The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
            • Record: found
            • Abstract: found
            • Article: found

            The Immune Landscape of Cancer

            We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio, extent of intratumoral heterogeneity, aneuploidy, extent of neoantigen load, overall cell proliferation, expression of immunomodulatory genes, and prognosis. Specific driver mutations correlated with lower (CTNNB1, NRAS, or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte levels across all cancers. Multiple control modalities of the intracellular and extracellular networks (transcription, microRNAs, copy number, and epigenetic processes) were involved in tumor-immune cell interactions, both across and within immune subtypes. Our immunogenomics pipeline to characterize these heterogeneous tumors and the resulting data are intended to serve as a resource for future targeted studies to further advance the field.
              • Record: found
              • Abstract: found
              • Article: not found

              Tumour-associated macrophages as treatment targets in oncology

              Tumour-associated macrophages (TAMs) are key drivers of tumour-promoting inflammation and cancer progression, and are important determinants of responsiveness to a range of therapies. Herein, the authors summarize the roles of TAMs in cancer, and discuss the potential of TAM-targeted therapeutic strategies to complement and synergize with other anticancer treatments.

                Author and article information

                Journal
                Endocr Relat Cancer
                Endocr Relat Cancer
                ERC
                Endocrine-Related Cancer
                Bioscientifica Ltd (Bristol )
                1351-0088
                1479-6821
                16 August 2022
                01 November 2022
                : 29
                : 11
                : 589-598
                Affiliations
                [1 ]Centre for Endocrinology , Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
                [2 ]Department of Endocrinology , St Bartholomew’s Hospital, Barts Health NHS Trust. West Smithfield, London, UK
                [3 ]Department of Pathology , Royal London Hospital, Whitechapel, London, UK
                [4 ]Department of Endocrine Surgery , St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, UK
                Author notes
                Correspondence should be addressed to S A Akker: s.a.akker@ 123456qmul.ac.uk
                Author information
                http://orcid.org/0000-0003-2382-9711
                http://orcid.org/0000-0002-6721-6207
                http://orcid.org/0000-0003-3893-3116
                Article
                ERC-22-0020
                10.1530/ERC-22-0020
                9513653
                35975974
                0bbe9f2a-fef8-4dd0-9470-f9ac65b669c7
                © The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 25 July 2022
                : 16 August 2022
                Categories
                Research

                Oncology & Radiotherapy
                phaeochromocytoma,paraganglioma,immune cells,tumour microenvironment,macrophage,lymphocyte

                Comments

                Comment on this article

                Related Documents Log